The European Commission has approved Novartis‘s Piqray (alpelisib) in combination with Faslodex (fulvestrant) for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR /HER2-) and harbors a PIK3CA mutation. The approval, which follows a recent positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use, covers men and postmenopausal women who have experienced disease progression following endocrine therapy as a singular therapy. “Piqray is…
You must be logged in to read/download the full post.
The post EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation appeared first on BioNewsFeeds.